NCT05270928View on ClinicalTrials.gov

Study to Evaluate the Safety, Tolerance, Pharmacokinetics and Preliminary Efficacy of IBI346#CIBI346Y001#

PHASE1CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

April 27, 2022

Primary Completion Date

December 21, 2022

Study Completion Date

May 29, 2023

Conditions
Relapsed/Refractory Multiple Myeloma
Interventions
DRUG

IBI346

IBI346 Antibody and IBI346 CAR-T cell injection

Trial Locations (1)

215000

The First Affiliated Hospital of Soochow University, Suzhou

All Listed Sponsors
collaborator

Innovent Biologics (Suzhou) Co. Ltd.

INDUSTRY

lead

The First Affiliated Hospital of Soochow University

OTHER